Goran Bajic
Overview
Explore the profile of Goran Bajic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feldman J, Ramos A, Vu M, Maurer D, Rosado V, Lingwood D, et al.
Sci Immunol
. 2025 Jan;
10(103):eado9572.
PMID: 39854479
Understanding the naïve B cell repertoire and its specificity for potential zoonotic threats, such as the highly pathogenic avian influenza (HPAI) H5Nx viruses, may allow prediction of infection- or vaccine-specific...
2.
Malladi S, Jaiswal D, Ying B, Alsoussi W, Darling T, Dadonaite B, et al.
bioRxiv
. 2024 Dec;
PMID: 39713327
SARS-CoV-2 mRNA vaccines induce robust and persistent germinal centre (GC) B cell responses in humans. It remains unclear how the continuous evolution of the virus impacts the breadth of the...
3.
Clark J, Hoxie I, Adelsberg D, Sapse I, Andreata-Santos R, Yong J, et al.
Cell Rep
. 2024 Nov;
43(11):114922.
PMID: 39504245
Neutralizing antibodies correlate with protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also correlate...
4.
Maurer D, Vu M, Ramos A, Dugan H, Khalife P, Geoghegan J, et al.
bioRxiv
. 2024 Nov;
PMID: 39484545
Monoclonal antibodies (mAbs) targeting the influenza hemagglutinin (HA) have the potential to be used as prophylactics or templates for next-generation vaccines that provide broad protection. Here, we isolated broad, subtype-neutralizing...
5.
Fantin R, Clark J, Cohn H, Jaiswal D, Bozarth B, Civljak A, et al.
bioRxiv
. 2024 Jul;
PMID: 39071292
The emergence of highly contagious and immune-evasive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has required reformulation of coronavirus disease 2019 (COVID-19) vaccines to target those new variants specifically....
6.
Bloom N, Ramirez S, Cohn H, Parikh U, Heaps A, Sieg S, et al.
J Infect Dis
. 2024 Jul;
230(5):1187-1196.
PMID: 39036987
Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection remains unclear. We evaluated the effect of infusion...
7.
Clark J, Hoxie I, Adelsberg D, Sapse I, Andreata-Santos R, Yong J, et al.
bioRxiv
. 2024 Mar;
PMID: 38464151
Neutralizing antibodies correlate with protection against SARS-CoV-2. Recent studies, however, show that binding antibody titers, in the absence of robust neutralizing activity, also correlate with protection from disease progression. Non-neutralizing...
8.
Atanasoff K, Brambilla L, Adelsberg D, Kowdle S, Stevens C, Slamanig S, et al.
mBio
. 2023 Dec;
15(1):e0247723.
PMID: 38054729
The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential...
9.
Puente-Massaguer E, Beyer A, Loganathan M, Sapse I, Carreno J, Bajic G, et al.
Front Bioeng Biotechnol
. 2023 Jun;
11:1097349.
PMID: 37342504
Seasonal influenza viruses account for 1 billion infections worldwide every year, including 3-5 million cases of severe illness and up to 650,000 deaths. The effectiveness of current influenza virus vaccines...
10.
Atanasoff K, Brambilla L, Adelsberg D, Kowdle S, Stevens C, Hung C, et al.
bioRxiv
. 2023 May;
PMID: 37131698
Importance: The COVID-19 pandemic remains a significant public health concern for the global population; development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential...